Catalyst is designed to stimulate the formation of healthy bone tissue in spinal fusions and is made of a proprietary nanocrystalline structure that’s reabsorbed and replaced by new tissue, according to a news release. A study in Biomedical Journal of Scientific & Technical Research found Catalyst had a 93% spinal fusion rate and improvements in quality of life and pain after surgery.
The bone graft was launched in August 2021 and reached 1,000 patients in May 2023.
